These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

621 related articles for article (PubMed ID: 25757539)

  • 1. PI3K/AKT/mTOR pathway is activated after imatinib secondary resistance in gastrointestinal stromal tumors (GISTs).
    Li J; Dang Y; Gao J; Li Y; Zou J; Shen L
    Med Oncol; 2015 Apr; 32(4):111. PubMed ID: 25757539
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Frequent mono-allelic loss associated with deficient PTEN expression in imatinib-resistant gastrointestinal stromal tumors.
    Quattrone A; Wozniak A; Dewaele B; Floris G; Vanspauwen V; Van Looy T; Schöffski P; Rutkowski P; Sciot R; Debiec-Rychter M
    Mod Pathol; 2014 Nov; 27(11):1510-20. PubMed ID: 24743220
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New Mechanisms of mTOR Pathway Activation in KIT-mutant Malignant GISTs.
    Lasota J; Kowalik A; Felisiak-Golabek A; Zięba S; Wang ZF; Miettinen M
    Appl Immunohistochem Mol Morphol; 2019 Jan; 27(1):54-58. PubMed ID: 28777148
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bromodomain and extraterminal domain inhibitor enhances the antitumor effect of imatinib in gastrointestinal stromal tumours.
    Mu J; Sun P; Ma Z; Sun P
    J Cell Mol Med; 2020 Feb; 24(4):2519-2530. PubMed ID: 31957165
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Absence of human papillomavirus infection and activation of PI3K-AKT pathway in cervical clear cell carcinoma.
    Ueno S; Sudo T; Oka N; Wakahashi S; Yamaguchi S; Fujiwara K; Mikami Y; Nishimura R
    Int J Gynecol Cancer; 2013 Jul; 23(6):1084-91. PubMed ID: 23792604
    [TBL] [Abstract][Full Text] [Related]  

  • 6. KIT over-expression by p55PIK-PI3K leads to Imatinib-resistance in patients with gastrointestinal stromal tumors.
    Lai S; Wang G; Cao X; Luo X; Wang G; Xia X; Hu J; Wang J
    Oncotarget; 2016 Jan; 7(2):1367-79. PubMed ID: 26587973
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual Targeting of Insulin Receptor and KIT in Imatinib-Resistant Gastrointestinal Stromal Tumors.
    Chen W; Kuang Y; Qiu HB; Cao Z; Tu Y; Sheng Q; Eilers G; He Q; Li HL; Zhu M; Wang Y; Zhang R; Wu Y; Meng F; Fletcher JA; Ou WB
    Cancer Res; 2017 Sep; 77(18):5107-5117. PubMed ID: 28760855
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Co-targeting of ACK1 and KIT triggers additive anti-proliferative and -migration effects in imatinib-resistant gastrointestinal stromal tumors.
    He W; Xu L; Ding J; Song L; Yang W; Klooster I; Pilco-Janeta DF; Serrano C; Fang H; Jiang G; Wang X; Yu J; Ou WB
    Biochim Biophys Acta Mol Basis Dis; 2023 Jun; 1869(5):166690. PubMed ID: 36921738
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Direct engagement of the PI3K pathway by mutant KIT dominates oncogenic signaling in gastrointestinal stromal tumor.
    Bosbach B; Rossi F; Yozgat Y; Loo J; Zhang JQ; Berrozpe G; Warpinski K; Ehlers I; Veach D; Kwok A; Manova K; Antonescu CR; DeMatteo RP; Besmer P
    Proc Natl Acad Sci U S A; 2017 Oct; 114(40):E8448-E8457. PubMed ID: 28923937
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical Activity of PI3K Inhibitor Copanlisib in Gastrointestinal Stromal Tumor.
    García-Valverde A; Rosell J; Serna G; Valverde C; Carles J; Nuciforo P; Fletcher JA; Arribas J; Politz O; Serrano C
    Mol Cancer Ther; 2020 Jun; 19(6):1289-1297. PubMed ID: 32371592
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overexpressed Fatty Acid Synthase in Gastrointestinal Stromal Tumors: Targeting a Progression-Associated Metabolic Driver Enhances the Antitumor Effect of Imatinib.
    Li CF; Fang FM; Chen YY; Liu TT; Chan TC; Yu SC; Chen LT; Huang HY
    Clin Cancer Res; 2017 Aug; 23(16):4908-4918. PubMed ID: 28442505
    [No Abstract]   [Full Text] [Related]  

  • 12. Molecular mechanisms of secondary imatinib resistance in patients with gastrointestinal stromal tumors.
    Wang CM; Huang K; Zhou Y; Du CY; Ye YW; Fu H; Zhou XY; Shi YQ
    J Cancer Res Clin Oncol; 2010 Jul; 136(7):1065-71. PubMed ID: 20043176
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The activated targets of mTOR signaling pathway are characteristic for PDGFRA mutant and wild-type rather than KIT mutant GISTs.
    Sápi Z; Füle T; Hajdu M; Matolcsy A; Moskovszky L; Márk A; Sebestyén A; Bodoky G
    Diagn Mol Pathol; 2011 Mar; 20(1):22-33. PubMed ID: 21326036
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SOCS1 gene therapy has antitumor effects in imatinib-resistant gastrointestinal stromal tumor cells through FAK/PI3 K signaling.
    Sugase T; Takahashi T; Serada S; Fujimoto M; Ohkawara T; Hiramatsu K; Nishida T; Hirota S; Saito Y; Tanaka K; Miyazaki Y; Makino T; Kurokawa Y; Yamasaki M; Nakajima K; Hanasaki K; Kishimoto T; Mori M; Doki Y; Naka T
    Gastric Cancer; 2018 Nov; 21(6):968-976. PubMed ID: 29623544
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy.
    Tsurutani J; West KA; Sayyah J; Gills JJ; Dennis PA
    Cancer Res; 2005 Sep; 65(18):8423-32. PubMed ID: 16166321
    [TBL] [Abstract][Full Text] [Related]  

  • 16. KIT oncogenic signaling mechanisms in imatinib-resistant gastrointestinal stromal tumor: PI3-kinase/AKT is a crucial survival pathway.
    Bauer S; Duensing A; Demetri GD; Fletcher JA
    Oncogene; 2007 Nov; 26(54):7560-8. PubMed ID: 17546049
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PTEN promoter methylation and activation of the PI3K/Akt/mTOR pathway in pediatric gliomas and influence on clinical outcome.
    Mueller S; Phillips J; Onar-Thomas A; Romero E; Zheng S; Wiencke JK; McBride SM; Cowdrey C; Prados MD; Weiss WA; Berger MS; Gupta N; Haas-Kogan DA
    Neuro Oncol; 2012 Sep; 14(9):1146-52. PubMed ID: 22753230
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition effect of Peg-IFNα-2b and Imatinib alone or combination on imatinib-resistant gastrointestinal stromal tumors cell lines.
    Zhang LY; Huang JS; Pi ZM; Yu MY
    Int J Clin Exp Pathol; 2015; 8(9):11340-7. PubMed ID: 26617858
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Coordinated targeting of CK2 and KIT in gastrointestinal stromal tumours.
    Huang M; Yang W; Zhu J; Mariño-Enríquez A; Zhu C; Chen J; Wu Y; Quan Y; Qiu H; Li X; Chai L; Fletcher JA; Ou WB
    Br J Cancer; 2020 Feb; 122(3):372-381. PubMed ID: 31776458
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activation of PI3K/Akt/mTOR signaling pathway triggered by PTEN downregulation in the pathogenesis of Crohn's disease.
    Long SH; He Y; Chen MH; Cao K; Chen YJ; Chen BL; Mao R; Zhang SH; Zhu ZH; Zeng ZR; Hu PJ
    J Dig Dis; 2013 Dec; 14(12):662-9. PubMed ID: 23962154
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.